Randomized Controlled Trial
A neoadjuvant, randomized, open-label phase II trial of afatinib versus trastuzumab versus lapatinib in patients with locally advanced HER2-positive breast cancer.
Clin. Breast Cancer. 2015 Apr 1;15(2):101-9.
Randomized Controlled Trial
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Ann. Oncol. 2016 Mar 1; 27 (3): 417-23.
Multicenter Study
A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.
Breast Cancer Res. Treat. 2012 Jun 1; 133 (3): 1057-65.